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SYNTHESIS OF BENZOPROSTACYCLINS USING 
PALLADIUM CATALYSTS 
BACKGROUND OF THE INVENTION 
Prostacyclin (I, PGIZ), ?rst discovered in 1976, is one 
of the most potent natural inhibitors of blood platelet 
aggregation. (See S. Moncado et al., Nature, 263, 663 
(1976) and R. Johnson et al., Prostaglandins, 12, 915 
(1976)). Unfortunately, its low metabolic stability due to 
enol ether hydrolysis greatly diminished its pharmaco 
logical utility. Major interest of latehas focused on the 
synthesis of more stable, analogs, such as the benzopros 
tacyclins Ia-c, described by K. Ohno et al. in US. Pat. 
No. 4,301,164. 
15 20 
17 19 
OH 
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COZH 
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0 
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no on 
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la 1 n-C5H1 1 
lb 1 CH(Me)CHZCE CCH3 
These compounds similarly exhibit substantial inhibi 
tion of platelet aggregation. 
Present synthetic approaches to the benzoprostacy 
clins are very lengthy and rather inef?cient. For exam 
ple, the synthesis of compound la as reported by H. 
Nagase et al., Tetrahedron Lett., 31, 4493 (1990) requires 
23 steps. As reported by K. Ohno et al. in US. Pat. No. 
4,474,802, the synthesis of the C1-methyl ester of lb 
requires at least 17 steps. 
Therefore, a need exists for ef?cient methods to syn 
thesize benzoprostacyclins. 
SUMMARY OF THE INVENTION 
The present invention provides a method for the 
synthesis of benzoprostacyclins of general formula I1. 
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curls-cola] (11) 
R4 
I 
R20 / 15 CH-B-R5 
R8 R9 
wherein R1 is a pharmaceutically acceptable cation, H 
or (C1-C12)alkyl, preferably (C1-C4)a1kyl; R2 is H, 
(C1-C12)-alkyl, (C2-C1o)acyl or (C7-Ci3)aroyl; R8 is H 
or (C1—C12)alkyl, and R9 is 0R3 wherein R3 is H, 
(C1-C12)alky1, (C2—C1o)acyl, or (C7-C13)aroyl; or R8 
and R9 taken together are keto; R4 is H, F, methyl or 
ethyl; R5 is (C1-C5)alky1; A is —CH2~, —O--CH2——, 
——CH2-CH2-— or —CH=CH—, and B is ----(CH;. 
),,-—Z— wherein n is 0-4 and Z is -—CH2-—CH2—, 
—-CH:CH- or —C!EC—. 
In compound II, the bonds at cyclopentane ring posi 
tions 8, 9 11 and 12, individually are in either the alpha 
(extending below the plane of the cyclopentane ring, 
indicated by a broken line) or beta (extending above the 
plane of the cyclopentane ring, indicated by a wedged 
line) con?guration, with the "natural” con?guration 
shown for l. The all-alpha or all-beta con?gurations are 
readily prepared by the present method. The con?gura 
tion at C15 may be either (R) or (S). Preferably, the C3 
and C9 cyclopentane ring bonds are both alpha (the 
“natural” con?guration) or both beta. 
Two novel compounds which can be prepared in 
accord with the present method wherein R1, A, R2, R3, 
R4, B and R5 are as described hereinabove, are depicted 
below (Ila, IIb). 
CH2--A—CO2R1 (Ila) 
O 
o m 
R20 
Representative compounds of formula II, wherein 
A = —CH2-—CH2—-, R2 = R3 = R‘: H, B = —(CH2)3—— 
5,233,059 
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and R5=CH3, which were prepared in accord with the 
present method are listed in Table I, below. 
TABLE I 
Benzoprostacyclin Analogs 
Bond Orientation 
Compound NO. C3 C9 C12 C13 C15--OI'I 
16(R‘ = Et) 0. a a a C15 :0 
17 (R1 = Et) :1 a a a a 
18(R1 = £1) a a a a a 
17(R1 = H) a a a a a 
is (R1 = H) a a a a B 
19 (R1 = E!) B B B l3 (1 
The present invention is also directed to intermediate 
III, which is employed in the present synthetic method: 
/ I 
R20 
wherein R1 is (Cl-C12) alkyl and A and R2 are as de 
?ned above. Preferably, the 1,4-cyclopentenyloxy 
bonds are both alpha, R2 is H, and R1 is (C1-C4)alkyl. 
As used herein, the term “alkyl” includes branched or 
straight-chain alkyl groups, or (C3—C12)cycloalky1, 
preferably (C3-C6)cyc1oalkyl, Aroyl is preferably ben 
zoyl or naphthoyl, wherein the aryl ring is either unsub 
stituted or is substituted with 1-4 (C1-C4)alkyl or 14 
(C1—C4)alkoxy groups. The preferred acyl is acetyl. 
Preferably A and B are methylene (—CH2—) or ethyl 
ene (—CH2—CH2—). Preferred pharmaceutically 
acceptable cations are alkali metal salts, NI-I4+, or the 
carboxylic acid addition salts of non-toxic amines. 
In accord with the present method, a compound of 
the formula III, wherein R2 is as de?ned above, and 
preferably is H; R1 is as de?ned above, and preferably is 
(C1-C1z)alkyl and A is as de?ned above, and preferably 
is —CH;— or —CI-I2——CH2—, is reacted with a com 
pound of the formula IV: 
R7—CH=CH—C(R5)(R9)-CH(R‘)-B-R5 1v 
wherein R7 is H, tris(C1-C4)alkylSn or (phenyl)3Sn; R8 
is H or (C1-C12)alkyl and R9 is CR3; or R8 and R9 taken 
together are keto; and R3, R‘, B and R5 are as described 
hereinabove; in the presence of a catalytic amount of 
pa1ladium(O)(Pd(O)), and an organic base to directly 
yield the corresponding compound of formula II. When 
R7 is trialkylSn- or triphenylSn, preferably R8 is H and 
R9 is OH. Preferably, the reaction is carried out in the 
presence of an organic amine, preferably i-PrzNEt, 
most preferably also in the presence of a source of chlo 
ride ion (Cl'), such as an alkali metal chloride or a tet 
raalkylammonium chloride, such as n-Bu4NCl. 
When R8 and R9 together are keto, the keto group 
can then be reduced to the corresponding C15-hydroxy 
group by methods known to the art. Optionally, in 
either case, the C1-ester can then be saponi?ed if neces 
sary, to yield compounds of formula II wherein R1 is H, 
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and the CO2H group can also be converted into a phar 
maceutically-acceptable carboxylate salt. 
The moiety —CH:CH— may be cis or trans. It is 
preferably trans in compound IV, and cis in moieties A 
and B in compounds II or III. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The preparation of a preferred embodiment of inter 
mediate III is summarized in Scheme 1. 
ihsmLL 
0R 0R1 
1@ 1 R7 Ja ha 
exozc 
no 
9 
1 (R = H) a R1 R2 
2 (R : any‘) c 3 H CH2CH=CH2 
4 TBDMS CH2CH=CH2 
d 5 TBDMS cnzcno 
: 6 TBDMS E—CH2CH=CHC02Et 
1 TBDMS (CH2)3CO2Et 
g s n (cnmcozm 
Steps (a)—(g) are summarized in Table II below, 
wherein the numbers preceding the reactants are mole 
ratios: 1 mole of l-8, unless otherwise noted. 
TABLE II 
S thesis of Com und 9 
Step Reactams Yield 
a 1.2 ally] bromide, 94% 
1.2 K2CO3, acetone 
b 0.8 MeAlCIZ, —20‘ C. 70% 
c t-butyldimethylsilyl 90% 
chloride, imidazole 
d ozone, ~78‘ C/MegS 83% 
e Ph3P=CHCO2Et 83% 
f H1, cat. PtOz 90% 
g n-Bu4NF 94% 
h 1,5-cyclopentadiene 72% 
monoepoxide, 2% Pd(PPh3)4, 
THF 
The requisite regio- and stereochemistry is ef?ciently 
introduced by the palladium-catalyzed opening of a 
vinylic epoxide. See, D. R. Deardorff et a1., Tetrahedron 
Lezt., 26, 5615 (1984). 
The reaction of 9 with l-octen-3-one, n-Bu4NCl and 
i-PrzNEt, in a mole ratio to 9 of l0:1.1:2.5, respectively, 
proceeded in 43% yield in the presence of 5% 
Pd(OAc)2at 50° C. in DMF to give compound 16, as 
shown in Scheme 2, below. 
5,233,059 
Scheme 2 
5% Pd(OAc); 
9 l0 l-octen-3-one ; 
1.1 n-Bu4NCl 
2.5 i-PrzNEt 
50' C., DMF 
42% 
COZEI 
Mechanistically, this process is believed to involve 
(1) reduction of Pd(OAc); to Pd(O), (2) oxidative addi 
tion of the aryl iodide of 9 to Pd(O) (without apparent 
competitive displacement of the aryloxy group to form 
a rr-allylpalladium intermediate which would deacti 
vate the catalyst), (3) intermolecular syn insertion of the 
cyclopentene double bond to form a bicyclic alkylpal 
ladium intermediate which is blocked from syn palla 
dium B-hydride elimination by the hydroxy group, (4) 
enone insertion into the carbon-palladium bond, and 
?nally (5) palladium B-hydride elimination to the enone 
16 (subsequent palladium hydride decomposition of 
Pd(O) regenerates the catalyst and completes the cata 
lytic cycle). 
(S)-BINAL-H reduction of enone 16 in accord with 
the procedure of R. Noyori et al., J. Amer. Chem, Soc, 
106, 6717 (1984), was unselective, affording an easily 
separable 1:1 mixture of diastereomers in 50% yield, in 
accord with Scheme 3, below. 
Scheme 3 
. 3 S BlNAL-H 
racemic 16—(-)'——> 
-1o0' C.—%—78' c. 
COZR 
O 
+ 
H6 on 
17 (R = E!) 
(1:1) 
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-continued 
2.15.132 
COZR 
HO 
OH 
18 (R = Et) 
Saponi?cation of esters l7 (R=Et) and 18 (R=et) af 
forded the corresponding carboxylic acids 17 (R=H) 
and 18 (R=H) in 83% and 92% yields, respectively. 
These stereochemical difficulties can be overcome in 
part by replacing the 1-alken-3-one in Scheme 2 with 
chiral vinylic stannane 14 as shown in Scheme 4. A 
separable mixture of diastereomers l7 (R=Et) and 19 
(R=Et) was obtained in 30% overall yield. 
Scheme 4 
9 (racemic) + 
5% Pd(OAc); 
1.2 n-Bu4NC1 
n'Bu3Sn\/\:/\/V 215 i-PrgNEt 
5 12h; DMF 
0“ 30% 
14 
COzEt 
O 
Y 
7 
17 (R = Et) + 
S Y N I HETIC METHODOLOGY 
The compound which is the source of the Pd(O) 
catalyst is generally employed in an amount of about 
0.001-20 mol-%, preferably 0.1-10 mol-%, based on the 
compound of formula III. Useful catalysts include, for 
example, bis(dibenzylideneacetone)pa1ladium (0), bis 
(isonitrile)palladium (O), bis-(cyclohexylisonitrile)pal 
ladium(O), bis-(isopropylisonitrile)palladium(0), bis 
(tert.-butylisonitrile)-palladium(O), bis-(p-tolylsioni 
trile)palladiurn(0), bis-(phenylisonitrile)palladium (O), 
and bis-(p-methoxyphenylisonitrile)palladium (O). 
Other Pd~containing compounds, e.g., Pd(Il) com 
pounds, can also be used in the present method under 
conditions wherein Pd(O) is generated. These include 
PdClz, palladium?l) carboxylate salts, such as 
Pd(OAc)2, PdBrz, Pd(CN)2, Pd(NO3)2 and the like. 
5,233,059 
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Other Pd catalysts which can be used in the present 
method include those disclosed in Blaser et al. (U 5. Pat. 
No. 4,335,054) at Col. 6, line 5 to Col. 7, line 3. 
Bases used in the present process can be inorganic or 
organic bases, which are adequately soluble in the reac 
tion medium. Representative bases are disclosed at Col. 
7, lines 8-65 of the Blaser et al. patent. Inorganic bases 
for use in the present process include N32CO3, KI-ICO3, 
LI2CO3, and NaI-ICO3. Useful organic bases include 
trialkylamines, such as diisopropyl(ethyl)amine. Prefer 
ably, organic bases are used. The preferred mole ratio of 
the base to the compound of formula III is about 2-3zl. 
A source of halide, such as chloride ion, is also prefer 
ably used in the present process, in an amount effective 
to promote the reaction and increase the yield. Organic 
chloride sources such as tetra(alkyl)ammonium chlo 
rides, wherein the alkyls can each be about (Cg-C12) 
alkyl, are preferred, i.e., (n-Bu)4NCl. Alkali metal ha 
lides such as MX, wherein M is Li, Na, or K and X is Cl, 
Br or I, can also be used. Preferred in the present 
method are a mixture of diisopropyl(ethyl)amine and 
tetra-n-butylammonium chloride (n-Bu4NCl). The hal 
ide source is preferably used in only a slight excess over 
the compound of formula III, (1.1-1.5 equivalents). 
In carrying out the synthesis of the compound of 
formula II, the aryl iodide III is preferably combined 
with an excess of compound IV, e.g., preferable in a 
mole ratio of IIIzIV of about 1:1.25-20, in a suitable 
organic solvent. The reaction mixture is preferably 
stirred at about 20°-75° C. for about 5-48 hr. under an 
inert atmosphere. The crude product is extracted, i.e., 
into ethyl acetate and can be puri?ed by chromatogra 
phy. 
Useful organic solvents include tetrahydrofuran 
(T HP), ethers, glycol ethers, dimethylsulfoxide, di 
methylformamide (DMF), acetonitrile, acetamide, di 
methylacetamide, and hexamethylphosphoramide. 
Compounds of formula IV, wherein R7=H and R8 
and R9 taken together are keto, e.g., vinyl(alkyl or al 
kylene)ketones can be readily prepared, e.g., by the 
reaction of vinylmagnesium bromide with acid chlo 
rides of the general formula R5-B-(R4)CI-I-COCl, 
wherein R5, B and R4 are as described above. Com 
pounds of formula IV, wherein R7 is a trialkylstannyl 
group, R3 is H and R9 is OR3 can be prepared as dis 
closed by J. K. Stille, in Angew. Chem. Int. Ed. Eng]., 25, 
508 (1986), M. Ochiai et al., Tet. Letters, 24, 4025 (1983), 
and by G. Keck et al., J. Org. Chem, 52, 2958 (1987). 
For example tri-n-butyltin hydride can be reacted with 
a protected 3-hydroxy-l-alkyne as disclosed in US. Pat. 
No. 4,230,879. 
The reduction of C15-keto-benzoprostacyclins to 
yield compounds of formula II, wherein R3=H can be 
accomplished with borohydride reducing agents such 
as zinc borohydride or sodium borohydride, or with 
chiral reducing agents such as lithium aluminum hy 
dride/a, a'-binaphthol ((S)-BINAL-H), as described in 
detail in the working Examples, below and in Aldri 
chimica Acta, 6, 14 (1983). The free C11—OH or 
C15—OH groups can then be acylated or aroylated by 
conventional methodologies, e.g., via reaction with 
anhydrides or acid chlorides in the presence of an or 
ganic base. Compounds of formula II wherein R1 is 
alkyl can be converted into the corresponding carboyx 
lic acids by saponification with alkali metal hydroxides 
in alcoholic solvents followed by neutralization of the 
reaction mixture. Pharmaceutically-acceptable cations 
(RI) include alkali metal salts and the amine salts dis 
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closed in K. Ohno et' al. (US. Pat. No. 4,474,802), 
which is incorporated by reference herein. 
The reaction methodology employed to prepare 
compound 9, as outlined in Scheme 1, can be readily 
modi?ed to prepare other aryl iodides of general for 
mula III, e.g., by the use of aldehydes of varying chain 
length in step (e). Compound III wherein A is CH=CH 
and R2 is H is readily prepared by deprotecting com 
pound 6, e.g., via step (g). 
BIOASSAYS 
The compounds prepared by the present method 
exhibit potent platelet aggregation inhibiting activity 
and blood pressure decreasing activity by vasodilation. 
The efficacy of the compound to inhibit platelet aggre 
gation is examined according to Born’s method (Nature, 
194, 927 (1962)). The blood is collected from humans or 
anesthetized rabbits. The blood is anti-coagulated with 
a 3.8% aqueous solution of sodium citrate in an amount 
of a tenth volume of the blood and centrifuged for 10 
minutes at 200><g to obtain platelet rich plasma. After 
pretreatment of the platelet rich plasma with the benzo 
prostacyclin, aggregation is measured by aggregometer 
with arachidonic acid, adenosine-2-phosphate(ADP) or 
collagen as the aggregation inducer. It is shown that 
compounds 16 (R=Et), l7 (R=Et), l8 (R=Et), 17 
(R=H), l8 (R=H), and 19 (R=Et) exhibit potent in 
hibitory activity. 
To examine the efficacy of a benzoprostacyclin to 
reduce blood pressure, the blood pressure of the carotid 
artery of rats under pentobarbital anesthesia is mea 
sured. The compounds listed above are injected into the 
vein through an indwelling catheter. These compounds 
exhibit substantially the same activity as prostaglandin 
E1 at the same dose of 0.05 to 100 ug/kg and have a 
longer duration of action than prostaglandin E1. 
An anti-thrombotic agent containing any of these 
benzoprostacyclins as the active component may be 
applied to prevent clotting in extracorporeal circula 
tion, treatment of a disturbance of peripheral circulation 
such as Buerger’s disease and Raynaud’s disease, pre 
vention and treatment of myocardial infarction, angina 
pectoris and cerebral infarction, prevention of TIA, 
treatment of diabetic thrombosis and prevention and 
treatment of arteriosclerosis. 
For the treatment of Buerger’s disease, the pharmaco 
logically effective intravenous dose of a compound of 
the invention is 0.001 to 100 ug/kg/min. In case of 
using the compound as an anti-thrombotic agent, 0.001 
to 50 mg of the compound is orally administered to a 
patient one to three times a day, and in case of using the 
compound as a blood pressure-reducing agent, 0.01 to 
50 mg of the compound is orally administered to a pa 
tient one to three times a day. 
The benzoprostacyclins can be orally administered as 
a form of a solid substance containing excipients such as 
starch, lactose, and sucrose, or can be parenterally ad 
ministered in a form of a sterilized aqueous solution. 
Such a solution may contain another solute, for in 
stance, glucose or sodium chloride in an amount suffi 
cient to make the solution isotonic. Various prepara 
tions for oral administration, injections, infusions, eye 
drops and suppositories can be prepared. 
The invention will be further described by reference 
to the following detailed examples. 
5,233,059 
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EXAMPLE 1 
Preparation of Compound 2 
A solution of o-iodophenol (6.6 g, 30 mmol), allyl 5 
bromide (40 g, 33 mmol) and potassium carbonate (4.6 
g, 3.3 mmol) in 7.5 ml of acetone was re?uxed for 8 hr. 
The reaction mixture was diluted with 40 ml of water, 
and extracted with ether (2 X25 ml). The organic phase 
was washed with brine (25 ml), and then dried over 
MgSO4. Concentration, followed by flash chromatog 
raphy, gave compound 2 as a colorless oil: 6.8 g, 94% 
yield, 1H NMR (CDCl3) 6 7.77 (dd, J =17.4 and 10.5 
and 7.8 Hz, 1.5 Hz, 1 H, Ar), 7.27 (dt, J: 1.8 and 7.8 Hz, 
1 H, Ar), 6.80 (dd, J =7.8 and 1.2 Hz, 1 H, Ar), 6.70 (dt, 
J=7.8 and 1.2 Hz, 1 H, Ar), 6.06 (ddt, J=17.4 and 10.5 
and 7.8 Hz, 1 H, HC=C), 5.52 (dd, J=17.4 and 1.8 Hz, 
1 H, HC=C), 5.31 (dd, 1:105 and 1.2 Hz, 1 H, 
HC=C), 4.59 (dt, J=4.8 and 1.5 Hz, 2 H, CH2); 13C 
NMR (CDC13) 8 157.09, 139.51, 132.57, 129.35, 122.66, 
117.59, 112.58, 86.72, 69.68; IR (neat) 1582, 1477 cm-1. 
EXAMPLE 2 
Preparation of 6.a1lyl-2-iodopheno1 3 
To a solution of compound 2 (7.0 g, 27 mmol) in 130 
ml of hexane was added MeAlClg (Aldrich, 1.0 M in 
hexane, 22 ml 22 mmol) dropwise at -20" C. After the 
reaction mixture was stirred for 2 hr. at —20° C. under 
nitrogen, the reaction was quenched by adding water 
(40 ml) and the mixture slowly warmed to room tem 
perature with swirling. Ethyl acetate (30 ml) was added 
to the reaction mixture, then stirring was continued for 
5 min. After separating phases, the organic phase was 
washed with water (30 ml) and brine (30 ml), then dried 
and concentrated. The residue was puri?ed by ?ash 
chromatography with 15:1 hexane/EtOAc to give 
product 3: 4.9 g, 70% yield; R/=0.38 (20:1 hex 
ane/EtOAc); 1H NMR (CDC13) 6 7.51 (dd, J = 1.2 and 
7.8 Hz, 1 H, Ar), 7.07 (d, J=7.8 Hz, 1 H; Ar), 6.62 (t, 
J=7.8 Hz, 1 H, Ar), 5.98 (ddt, J: 17.4 and 9.6 and 6.6 
Hz, 1 H, HC=C), 5.37 (s, 1 H, OH), 5.12 (m, 1 H, 
CH=C), 5.07 (m, 1 H, CH=C), 3.43 (d, J=6.6 Hz, 2 H, 
CH2); 13C NMR (CDC13) 5 152.60, 136.33, 136.01, 
130.73, 126.81, 122.42, 116.22, 86.41, 35.56; IR (neat) 
3487 (OH), 1593, 1234 cm-1; LRMS m/z (relative in 
tensity) 51.1 (34), 77.1 (47), 105.1 (58), 118.1 (41), 133.1 
(42), 260.0 (M+, 100). 
EXAMPLE 3 
Preparation of Compound 4 
To a solution of compound 3 (4.9 g, 18.7 mmol) and 
irnidazole (3.2 g, 47.1 mmol) in 20 ml of DMF was 
added t-butyldimethylsilyl chloride (3.1 g, 20.5 mmol) 
dissolved in 15 mmol of DMF at room temperature 
under nitrogen. After the mixture was stirred for 12 hr. 
at room temperature, it was extracted with hexane (50 
mlX8). The hexane phase was concentrated and then 
?ash chromatographed to give compound 4: 6.3 g, 90% 
yield; Rj=0.52 (hexane); 1H NMR (CDC13) 8 7.63 (dd, 
J=7.8 and 1.8 Hz, 1 H, Ar), 7.11 (dd J=7.8 and 1.8 H2, 
1 H, Ar), 6.66 (t, J =7.8 Hz, 1 H, Ar), 5.86 (ddt, J: 17.4 
and 9.6 and 6.6 Hz, 1 H, C=CHCH;), 5.08 (m, 2 H, 
HZC=C), 3.39 (d, J=6.9 Hz, 2 H, CH2), 1.06 (s, 9 H, 
t-BuSi), 0.331 (s, 6 H, SiMeZ). 
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EXAMPLE 4 
Preparation of Compound 5 
Ozone was passed through a solution of compound 4 
(722 mg, 1.9 mmol) in 19 ml of methanol at —78° C. 
until the deep blue color persisted (about 15 min.) The 
reaction was ?ushed with nitrogen gas and 8 ml of 
CH3SCH3 was added at --78° C. The reaction mixture 
was then allowed to stir for 30 min. at --78° C., for 1 hr. 
at 0° C and for another 30 min. at room temperature. 
The methanol solvent was evaporated under reduced 
pressure, and 60 ml of ether was then added to the 
residue. After the mixture was washed with water (10 
ml) and brine (20 ml X 2), it was dried and concentrated. 
Flash chromatography gave product 5: 638 mg, 83% 
yield; Rf=0.63 (3:1 hexane/EtOAc); 1H NMR (CDC13) 
6 9.63 (t, J=2.1 Hz, 1 H, CH0), 7.74 (dd, J=8.1 and 1.5 
Hz, 1 H, Ar), 7.09 (dd, J=7.5 and 1.5 Hz, 1 H, Ar), 6.72 
(t, J=7.5 Hz, 1 H, Ar), 3.68 (d, J=2.1 Hz, 2 H, CH2), 
1.05 (s, 9 H, t-BuSi), 0.32 (s, 6 H, SiMeg); 13C NMR 
(CDC13) 8 199.34, 153.92, 139.70, 131.54, 124.26, 123.81, 
91.23, 46.16, 26.37, 18.85, —1.52. 
EXAMPLE 5 
Preparation of Compound 6 
To a solution of (carboxymethylene)triphenylphos 
phorane (Aldrich, 3.88 g, 11.5 mmol) dissolved in 30 ml 
of CHgClZ was added dropwise at room temperature 
aldehyde 5 (3.57 g, 9.3 mmol) dissolved in 14 ml of 
CHzClz. After the reaction was stirred for 12 hr. at 
room temperature, it was concentrated in vacuo and 
puri?ed by ?ash chromatography with 5:1 hex 
ane/EtOAc to give ester 6: 3.52 g, 83% yield; Rf=0.46 
(5:1 hexane/EtOAc); 1H NMR (CDCl3) 6 7.67 (dd, 
J=7.8 and 1.5 Hz, 1 H, Ar), 7.05 (dd, J=7.5 and 1.5 Hz, 
1 H, Ar), 6.99 (dt, 1: 15.6 and 6.6 Hz, 1 H, HC=C) 6.66 
(t, J=7.5 Hz, 1 H, Ar), 5.80 (d, J=15.6 Hz, 1 H, 
CH=C), 4.18 (q, J=7.2 Hz, 2 H, OCHZ), 3.53 (dd, 
1:69 and 1.5 Hz, 2 H, CH2), 1.27 (t, J=7.2 Hz, 3 H 
CH3), 1.05 (s, 9 H, t~BuSi), 0.32 (s, 6 H, MegSi); l3C 
NMR(CDC13)8 166.32, 153.31, 146.18, 138.75, 130.60, 
129.52, 123.61, 122.93, 91.09, 60.36, 33.94, 26.42, 18.94, 
. 14.32, —1.49. 
EXAMPLE 6 
Preparation of Compound 7 
To a three neck ?ask equipped with a hydrogen-?lled 
gas balloon were added a,B-unsaturated ester 6 (619 
mg, 1.36 mmol), ethanol (20 ml), 2 N aqueous HCl (0.4 
m1) and PtOz (Aldrich, 60 mg). The reaction was 
?ushed with hydrogen gas using an aspirator, and then 
stirred for 1 hr. at room temperature under the hydro 
gen balloon pressure. After the reaction was neutralized 
with 3 N aqueous NaOH (0.27 ml), it was poured into 
100 ml of ethyl acetate (EtOAc). The solution was 
washed with brine (50 ml, 25 ml) and concentrated in 
vacuo. The residue was puri?ed by ?ash chromatogra 
phy to give compound 7: 562 mg, 90% yield; R_/=0.52 
(7:1 hexane/EtOAc); 1H NMR (CDC13) 87.62 (dd, 
J=7.8 and 1.5 Hz, 1 H, Ar), 7.10 (dd, J=7.8 and 1.5 Hz, 
1 H, Ar), 6.64 (t, J=7.8 Hz, 1 H, Ar), 4.11 (q, J=7.2 Hz, 
2 H, OCHZ), 2.66 (t, J =7.8 Hz, 2 H, CH2), 2.27 (t, 
J=7.5 Hz, 2 H, CH2), 1.88 (m, 2 H, CH2), 1.25 (t, J=7.2 
Hz, 3 H, CH2), 1.04 (s, 9 H, t-BuSi), 0.32 (s, 6 H, SiMeg). 
5,233,059 
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EXAMPLE 7 
Preparation of Compound 8 
To a solution of compound 7 (2.85 g, 6.2 mmol) in 60 
ml of THF at —78° C. was added n-Bu4NF (Aldrich, 
1.0 M in THF, 6.2 ml, 6.2 mmol). The reaction mixture 
was stirred for 1 hr. at —78° C., then allowed to warm 
to 0° C., and quenched by adding water (10 ml). The 
mixture was poured into 50 ml of ethyl acetate, and 
washed with water (25 ml) and brine (20 ml). The or 
ganic phase was dried and concentrated. The residue 
was puri?ed by ?ash chromatography with 4:1 hex 
ane/EtOAc to give compound 8: 2.02 g, 94% yield; 
Rf: 0.37 (5:1 hexane/EtOAc); 1H NMR (CDC13) 8 7.53 
(dd, J=7.8 and 1.2 Hz, 1 H, Ar), 7.05 (dd, J=7.8 and 1.2 
Hz, 1 H, Ar), 6.58 (t, J=7.8 Hz, 1 H, Ar), 6.18 (s, 1 H, 
OH), 4.15 (q, J=7.2 Hz, 2 H, CH2), 2.69 (t, J :72 Hz, 
2 H, CH2), 2.36 (t, J :72 Hz, 2 H, CH2), 1.91 (m, 2 H, 
CH2), 1.27 (t, J :72 Hz, 3 H, CH3); 13C NMR (CDC13) 
8 174.15, 152.96, 136.44, 130.64, 128.05, 122.06, 86.28, 
60.59, 33.28, 30.54, 24.68, 14.24; IR (neat) 3373 (OH), 
2980, 2957, 1707 (C=O), 1445 cm -1. HRMS m/z cal 
culated for C12H15O3l 334.00660, found 334.00617. 
EXAMPLE 8 
Preparation of Compound 9 
To a dried ?ask was added Pd(PPh3)4 (18 mg, 0.016 
mmol). To this was added compound 8 (264 mg, 0.79 
mmol) in 2 ml of THF, and the reaction mixture was 
stirred in an ice-water bath. Cyclopentadiene mono 
epoxide (97 mg, 1.18 mmol) in 2 ml of THF was added 
dropwise at 0° C, and stirring was continued for 20 min. 
at this temperature and another 24 hr. at room tempera 
ture. The reaction mixture was concentrated. The resi 
due was purified by ?ash chromatography with 2:1 
hexane/EtOAc to give product 9: 235 mg, 71% yield; 
R]: 0.27 (2:1 hexane EtOAc); 1H NMR (CDC13) 5 7.58 
(dd, J=7.8 and 1.5 Hz, 1 H, Ar), 7.15 (dd, J=7.8 and 1.5 
Hz, 1 H, Ar), 6.77 (t, J=7.8 Hz, 1 H, Ar), 6.09 (m, 1 H, 
HC=C), 6.01 (m, 1 H, HC=C), 5.11 (m, l H, CHOAr), 
4.68 (m, 1 H, CHOH), 4.12 (q, J :72 Hz, 2 H, OCHZ), 
2.85 (m, 2 H), 2.60 (ddd, J: 15.3 and 9.6 and 6.0 Hz, 1 
H, CH2 in cyclopentane), 2.30 (dt, J = 1.8 and 6.9 Hz, 2 
H), 2.06 (dt, 1: 14.7 and 3.9 Hz, 1 H, CH2 in cyclopen 
tane), 1.88 (m, 2 H), 1.25 (t, J=6.3 Hz, 3 H, CH3), 0.88 
(m, 1 H, OH); 13C NMR (CDC13) 8 173.69, 156.22, 
138.09, 137.98, 136.65, 133.55, 130.56, 125.87, 92.45, 
85.71, 74.97, 60.52, 41.28, 33.50, 30.86, 25.47, 14.28; IR 
(neat) 3350 (OH, 2959, 1720 (C=O), 1599, 1462, 1352 
cm— 1; HRMS m/z calculated for C17H11O4I 416.04847, 
found 416.04747. 
EXAMPLE 9 
Preparation of Compound 16 
In a vial were placed compound 9 (94 mg, 0.23 
mmol), l-octen-3-one (285 mg, 2.3 mmol), n-Bu4NCl 
(Lancaster, 70 mg, 0.25 mmol), i-PrzNEt (98 1.1L, 0.58 
mmol), Pd(OAc)2 (2.5 mg, 0.011 mmol) and DMF (0.46 
ml). After the reaction was stirred for 12 hr. at 50° C., it 
was poured into 40 ml of EtOAc. The mixture was 
washed with saturated NH4C1 (15 ml) and then the 
aqueous phase was back-extracted with EtOAc (15 ml). 
The overall organic phase was washed with brine (15 
ml), and then dried over MgSO4 and concentrated 
under reduced pressure. The residue was puri?ed by 
?ash chromatography to give product 16: 37 mg, 42% 
yield; Rf_—0.44 (1:1 hexane/EtOAc); 1H NMR (CDC13) 
5 
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6 6.94 (d, J=7.5 Hz, 1 H, Ar), 6.88 (d, J=7.5 Hz, 1 H, 
Ar), 6.85 (dd, J= 15.9 and 9.9 Hz, 1 H, C=CH), 6.75 (t, 
J=7.5 Hz, 1H, Ar), 6.21 (d, J: 19.5 Hz, 1 H, HC=C), 
5.39 (dd, J: 8.1 and 6.0 Hz, 1 H, CHOAr), 4.30 (m, 1 H, 
CHOH), 4.12 (m, 2 H), 3.99 (t, J=8.4 Hz, 1 H), 2.85 (dt, 
J=3.9 and 9.6 Hz, 1 H), 2.55 (m, 4 H), 2.26 (m, 2 H), 
2.18 (ddd, J=15.3 and 6.0 and 4.5 Hz, 1 H, CH2 in 
cyclopentane), 2.02 (m, 2 H), 1.88 (m, 1 H), 1.63 (m, 2 
H), 1.28 (m, 7 H, CHz’s and OCH2CH3), 0.89 (t, J =6.9 
Hz, 3 H, CH3); 13C NMR (CDC13) a 200.94, 173.79, 
157.68, 144.27, 132.17, 129.05, 127.05, 123.61, 123.20, 
120.06, 88.92, 76.69, 60.26, 52.63, 50.69, 43.01, 38.94, 
33.36, 31.46, 28.94, 24.81, 24.00, 22.42, 14.22, 13.90; IR 
(neat) 3464 (OH), 2932, 1732 (C=O), 1688 (C=O), 1465 
cm-1; HRMS m/z calculated for C25H34O5 414.24063, 
found 414.24118. 
EXAMPLE 10 
Preparation of Compounds 17 (R=Et) and 18 (R=Et) 
To a solution of LiAlH4 (Aldrich, 2.8 ml, 0.539 M in 
THF, 1.52 mmol) was added ethanol (0.76 ml, 2 M in 
THF, 1.52 mmol) dropwise over 10 min. at room tem 
perature. Subsequently, a THF solution of (S)-binaph 
thol (Aldrich, 429 mg, 1.52 mmol in 2.4 ml of THF) was 
added dropwise, and the resulting mixture was stirred 
for 30 min. Enone 16 (199 mg, 0.51 mmol) in 2 ml of 
THF was added dropwise over 3 min. at - 100° C., and 
stirring was continued for 2 hr at —100“ C. and for 
another 2 hr at —78° C. The reaction was quenched by 
adding methanol (0.5 ml) at —78° C. and warmed to 
room temperature. After addition of water (0.5 ml) and 
ether (15 ml), stirring was continued for an additional 30 
min. To this mixture was added anhydrous MgSO4 and 
the mixture was ?ltered through Celite. Concentration, 
followed by ?ash chromatography with 1:2 hex 
ane/EtOAc, gave compounds 17 (R=Et, 49 mg, 25% 
yield) and 18 (R=Et, 50 mg, 25% yield). 
Compound 17 (R=Et): RF0.25 (1:2 hexane/ 
—EtOAc); 1H NMR (CDC13) 8 6.91 (d, J =7.5 Hz, 2 H, 
Ar), 6.73 (t, J=7.5 Hz, 1 H, Ar), 5.66 (m, 2 H, 
HC=CH), 5.33 (t, J :78 Hz, 1 H, CHOAr), 4.20 (m, l 
H, CHOH), 4.10 (m, 3 H, OCH; and C=CHCHOH), 
3.87 (t, J :87 Hz, CHAr), 2.74 (m, 1 H), 2.64 (dd, 
J: 12.9 and 6.6 Hz, 1 H), 2.55 (dt, J=2l.3 and 7.2 Hz, 1 
H), 2.38 (d, J = 15.0 Hz, 1 H, CH2 in cyclopentane), 2.27 
(dt, J=2.1 and 1.8 Hz, 1 H), 2.15 (ddd, 1:150 and 6.0 
and 4.5 Hz, 1 H, CH211‘1 cyclopentane), 2.04-1.78 (m, 4 
H), 1.67 (br s, 2 H, OH’s), 1.54 (m, 1 H), 1.33 (m, 6 H), 
1.25 (t, J =7.5 Hz, 3 H, CH3), 0.92 (t, J =6.3 Hz, CH3); 
13C NMR (CDC13) 6 173.90, 157.81, 136.44, 128.73, 
128.15, 127.76, 123.91, 122.99, 119.82, 88.28, 76.93, 
72.96, 60.30, 52.28, 50.04, 42.37, 37.04, 33.52, 31.81, 
29.06, 25.25, 24.89, 22.69, 14.29, 14.10; IR (neat) 3486 
(OH), 1732 (C=O) cm-l; HRMS m/z calculated for 
C25H36O5 416.25628, found 416.25541. 
Compound 18 (R=Et): Rj=0.48 (1:2 hexane/ 
—EtOAc); 1H NMR (CDC13) 8 6.97 (d, J =7.2 Hz, 1 H, 
Ar), 6.92 (d, J =7.5 Hz, 1 H, Ar), 6.74 (t, J =7.5 Hz, 1 H, 
Ar), 5.71 (m, 2 H, HC=CH), 5.34 (t, J :69 Hz, 1 H, 
CHOAr), 4.19 (m, 1 H, CHOH), 4.11 (m, 3 H, OCH; 
and C=CHCHOH), 3.90 (t, J =11.7 Hz, 1 H, CHAr), 
2.75 (m, l‘ H), 2.59 (m, 1 H), 2 38 (d, J=15.0 Hz, 1 H, 
CH1 in cyclopentane), 2.27 (m, 2 H), 2.16 (ddd, J = 15.0 
and 6.0 and 4.5 Hz, 1 H, OH; in cyclopentane), 
2.05-1.82 (m, 4 H), 1.72 (d, J=6.0 Hz, 1 H), 1.53 (br s, 
2 H, OH’s), 1.29 (m, 6 H), 1.25 (t, J =7.5 Hz, 3 H, CH3), 
0,88 (m, 3 H, CH3); 13C NMR (CDC13) 6 173.87, 157.69, 
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136.34, 128.70, 127.76, 127.08, 124.04, 122.95, 119.85, 
88.23. 77.02, 72.53, 60.27, 52.38, 50.06, 42.52, 37.27, 
33.49, 31.80, 29.04, 25.19, 24.86, 22.63, 14.27, 14.10; IR 
(neat) 3416 (OH), 3053, 2845, 1732 (C20), 1599, 1447 
cm-1; HRMS m/z calculated for C25H36O5 416.25628, 
found 416.25711. 
EXAMPLE 11 
Preparation of Compounds 17 (R=Et) and 19 (R=Et) 
In a vial were placed compound 9 (109 mg, 0.26 
mmol), 'y-stannyl alcohol 14 (164 mg, 0.39 mmol), i 
PrzNEt (85 mg, 0.66 mmol), n-Bu4NCl (Lancaster, 88 
mg, 0.31 mmol), Pd(OAc)2 (2.9 mg, 0.013 mmol) and 
DMF (0.52 ml) as a solvent. After the resulting mixture 
was stirred for 12 hr. at room temperature, it was passed 
through a silica gel pad with 1:2 hexane/EtOAc. The 
solution was concentrated, and the residue was puri?ed 
by ?ash chromatography with 1:2 hexane/EtOAc to 
give compounds 17 (R=Et, 15 mg, 14% yield) and 19 
(R=Et, 17 mg, 16% yield). The spectral data for com 
pound 19 are the same as those of compound 18 
(R=Et). 
EXAMPLE 12 
Preparation of 12-epi-5,6,7-trinor-4,8-inter-m-phenylene 
P611 [17 (R=H)]. 
To a solution of compound 17 (R=Et, 22 mg, 0.06 
mmol) in 0.74 ml of THF was added 3 N aqueous 
NaOH (0.37 ml) at room temperature. After the mixture 
was stirred for 6 days at room temperature, it was neu 
tralized by 2 N aqueous HCl. The organic phase was 
decanted with EtOAc, and then dried over MgSO4. 
Concentration, followed by ?ash chromatography with 
20:1 EtOAc/MeOH, gave product 17 (R=H): 17 mg, 
83% yield; Rf =0.29 (20:1 EtOAc/MeOH); 1H NMR 
(CDC13) 8 6.90 (d, J=7.5 Hz, 1 H, Ar), 6.89 (d, J=7.5 
Hz, 1 H, Ar), 6.72 (t, J=7.5 Hz, 1 H, Ar), 5.61 (m, 2 H, 
HC=CH), 5.31 (dd, J=0.9 and 7.8 Hz, 1 H, CHOAr), 
4.30 (br s, 2 H, OH’s), 4.18 (m, 1 H, CHOH), 4.03 (m, 1 
H, C=CCHOH), 3.85 (t, J=9.0 Hz, 1 H, CHAr), 
2.75-2.65 (m, 2 H), 2.53 (m, 1 H), 2.36 (d, J: 15.0 Hz, 1 
H, CH2 in cyclopentane), 2.26 (m, 2 H), 2.17-2.01 (m, 2 
H), 1.81 (m, 1 H), 1.53 (m, 3 H), 1.32 (m, 6 H), 0.91 (t, 
J=6.9 Hz, 3 H, CH3) 13C NMR (CDC13) 8 177.93, 
157.99, 136.35, 128.91, 128.29, 127.65, 123.97, 122.80, 
119.98, 88.37, 77.00, 73.04, 52.18, 49.95, 42.02, 36.96, 
32.89, 31.83, 28.83, 25.28, 24.85, 22.73, 14.12; IR (neat) 
3383 (OH), 2928, 1709 (C=O), 1595, 1454 cm—1; 
HRMS m/z calculated for C23H31O5 388.22497, found 
388.22406. Anal. Calcd for C23H32O5: C, 71.11; H, 8.30. 
Found: 70.75; H, 8.92. 
EXAMPLE 13 
Preparation of 
12,15-epi-5,6,7-trinor-4,S-inter-m-phenylene PGI; [18 
(R=H)] 
To a solution of compound 18 (R=Et, 55 mg, 0.14 
mmol) in 1.8 ml of THF was added 3 N aqueous NaOH 
(0.9 ml) at room temperature. After the reaction was 
stirred for 6 days at room temperature, it was neutral 
ized by 2 N aqueous HCl. The organic phase was de 
canted with ethyl acetate and dried over MgSO4. Con 
centration in vacuo followed by ?ash chromatography 
with 20:1 EtOAc/MeOH gave compound 18 (R=H): 
47 mg, 92% yield; R/=0.37 (20:1 EtOAc/MeOH); 1H 
NMR (CDClz) 6 6.94 (d, J=7.5 Hz, 1 H, Ar), 6.90 (d, 
J=7.5 Hz, 1 H, Ar), 6.74 (t, J=7.5 Hz, 1 H, Ar), 5.72 
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(dd, 1:153 and 5.1 Hz, 1 H, HC=C), 5.65 (dd, J: 15.3 
and 7.8 Hz, 1 H, C=CH), 5.62 (br s, 2 H, CH5), 5.32 (t, 
J :69 Hz, 1 H, CHOAr), 4.20 (m, 1 H, CHOH), 4.12 
(dd, J=12.0 and 9.0 Hz, 1 H, CZCHCHOH), 3.89 (t, 
J=8.7 Hz, 1 H), 2.80 (dt, J=4.2 and 9.0 Hz, 1 H), 2.70 
(m, 1 H), 2.54 (m, 1 H), 2.38 (d, J: 15.9 Hz, 1 H, CH2 in 
cyclopentane), 2.29 (dd, J = 14.1 and 6.3 Hz, 2 H), 
2.22-2.04 (m, 2 H), 1.84 (m, 1 H), 1.49 (m, 3 H), 1.29 (m, 
6 H), 0.89 (t, J=6.3 Hz, 3 H, CH3); 13C NMR (CDC13) 
6 178.54, 157.87, 136.26, 128.88, 127.64, 126.73, 124.15, 
122.72, 119.92, 88.00, 76.93, 72.39, 52.27, 49.92, 42.12, 
37.19 33.07, 31.81, 28.97, 25.17, 24.64, 22.64, 14.13; IR 
(neat) 3412 (OH), 3271 (OH), 3063, 2924, 2858, 1709 
(C=O), 1456, 1254 cm—1; HRMS m/z calculated for 
C23H32O5 388.22497, found 388.22589. Anal. Calcd for 
C23H32O5; C, 71.11; H, 8.30. Found: C, 70.36, H, 8.09. 
All patents, patent documents and publications cited 
herein are incorporated by reference herein, as though 
fully set forth. 
The invention has been described with reference to 
various speci?c and preferred embodiments and tech 
niques. However, it should be understood that many 
variations and modi?cations may be made while re 
maining within the spirit and scope of the invention. 
What is claimed is: 
1. A method for preparing benzoprostacyclins com 
prising reacting a compound of the general formula 
(III): 
CH2—A_CO2R1 (III) 
R20 
wherein R1 is a pharmaceutically-acceptable cation, H 
01' (C1-C11)a1kyl; A iS —CH2—, -—-O—CH2—, 
CH2—CH2— or -CH=CH—; and R2 is H, (C1-C1 
2)a1kyl, (C2—C10)8cyl 0r (C7—C13)aroyl with a molar 
excess compound of a general formula (IV): 
R7—CH=CH—C(Ra)(R9)-CH(R4)-B-R5 (IV) 
wherein R5 is (C|-C5)a1ky1; B is —(CH2),,—Z wherein 
n is 0-4 and Z is —CH2CH2—, —CH=CH— or 
—CI=C—; R‘ is H, F, CH3 or CH2CH3; and R7 is 
((C1—C4)alkyl)3Sn, (phenyl)3Sn or H; R8 is H or (C1-C1. 
2)alkyl; and R9 is CR3, wherein R3 is H, (C1-C12)alkyl, 
(C2—C10)acyl or (C7-C13)aroy1, or R8 and R9 taken to 
gether are keto; wherein the reaction is carried out at 
about 20°-75° C. for about 5-48 hrs in an organic sol 
vent in the presence of a catalytic amount of Pd(0), and 
an organic amine to yield a compound of the formula 
(II): 
5,233,059 
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wherein R1, A, R2, R8, R9, R4, B and R5 are as de?ned 
above. 
2. The method of claim 1, wherein R8 and R9 taken 
together are keto in compound II, further comprising 
reducing the C15-keto group of compound II with a 
reducing agent to yield a compound of formula 11 
wherein R8 is H and R9 is OH. 
3. The method of claim 1 wherein R7 is (n-butyl)3Sn, 
R8 is H and R9 is OH. 
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4. The method of claim 1, wherein compound II 
comprises (S)C15—OH. 
5. The method of claim 4 wherein the C11-—OR2 bond 
is in the alpha-con?guration. 
6. The method of claim 1 wherein, in compound III, 
R1 is (C1-C12)alkyl and R2 is H. 
7. The method of claim 6, further comprising saponi 
fying the COZR1 moiety of compound II to yield COZH. 
8. The method of claim 7, further comprising forming 
a pharmaceutically-acceptable alkali metal salt, ammo 
nium, or amine salt of the moiety COZH. 
9. The method of claim 1 wherein the Pd(O) is 
formed in situ from a Pd(II) compound. 
10. The method of claim 9 wherein the Pd(II) com 
pound is Pd(OAc)2. 
11. The method of claim 1 wherein the organic base 
comprises a tri(Cz-C12)alkylamine. 
12. The method of claim 11 wherein the organic 
amine comprises diisopropyl(ethyl)amine. 
13. The method of claim 1 wherein the mole ratio of 
III:IV is about 1:1.25-20. 
14. The method of claim 6 wherein A is —CH;— or 
-—CH2—CH2—- and B is CH2—CH2—-CH2. 
15. The method of claim 14 wherein R4 is H and R5 is 
CH3. . 
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